EZH2 and neoplasm: In view of our findings indicating the activation of STAT3 signaling pathway through the degradation of SUZ12 and EZH2 mediated by SUMOylated HSPA9, we investigated the role of STAT3 in MUL1-induced tumor inhibition effects.